Cargando…

Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation

IMPORTANCE: The Centers for Medicare & Medicaid Services requires health care organizations to report the National Clinical Trial (NCT) identifier on claims for items and services related to clinical trials that qualify for coverage. This same NCT identifier is used to identify clinical trials i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Green, Angela K., Tabatabai, Sara M., Bai, Xing, Mishra Meza, Akriti, Lesny, Anne-Marie, Aghajanian, Carol, Landgren, Ola, Riely, Gregory J., Sabbatini, Paul, Salner, Andrew, Lipkin, Scott, Ip, Andrew, Bach, Peter B., Begg, Colin B., Mailankody, Sham, Lipitz-Snyderman, Allison
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941352/ https://www.ncbi.nlm.nih.gov/pubmed/35315914 http://dx.doi.org/10.1001/jamanetworkopen.2022.3687

Ejemplares similares

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations
por: Lipitz‐Snyderman, Allison, et al.
Publicado: (2023)

Electronic consent in clinical care: an international scoping review
por: Chimonas, Susan, et al.
Publicado: (2023)

Assessment of variation in 30‐day mortality following cancer surgeries among older adults across US hospitals
por: Lipitz‐Snyderman, Allison, et al.
Publicado: (2020)

Risk for Clostridiodes difficile Infection among Older Adults with Cancer
por: Kamboj, Mini, et al.
Publicado: (2019)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Persistence of Telemedicine Usage for Breast and Prostate Cancer after the Peak of the COVID-19 Pandemic
por: Chimonas, Susan, et al.
Publicado: (2023)

Impact of a statewide intensive care unit quality improvement initiative on hospital mortality and length of stay: retrospective comparative analysis
por: Lipitz-Snyderman, Allison, et al.
Publicado: (2011)

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
por: Mitchell, Aaron P, et al.
Publicado: (2022)

Association between cancer‐specific adverse event triggers and mortality: A validation study
por: Weingart, Saul N., et al.
Publicado: (2020)

Why Not? Persuading Clinicians to Reduce Overuse
por: Chimonas, Susan C., et al.
Publicado: (2020)

Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease
por: Hofmann, Jonathan N, et al.
Publicado: (2017)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Developing a cancer‐specific trigger tool to identify treatment‐related adverse events using administrative data
por: Weingart, Saul N., et al.
Publicado: (2020)

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study
por: Mitchell, Aaron P, et al.
Publicado: (2023)

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies
por: Mailankody, Sham, et al.
Publicado: (2016)

Multidisciplinary Treatment of Non-Spine Bone Metastases: Results of a Modified Delphi Consensus Process
por: Gillespie, Erin F., et al.
Publicado: (2022)

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021)

Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine
por: Prasad, Vinay, et al.
Publicado: (2015)

Dietary intake is associated with risk of multiple myeloma and its precursor disease
por: Thordardottir, Marianna, et al.
Publicado: (2018)

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
por: Korde, Neha, et al.
Publicado: (2023)

One committee to review it all: A single, multi-disciplinary COVID-19 research committee
por: Migliacci, Jocelyn, et al.
Publicado: (2022)

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research
por: Choudhury, Noura J., et al.
Publicado: (2021)

Clinically meaningful benefit: real world use compared against the American and European guidelines
por: Dreicer, Jessica J., et al.
Publicado: (2017)

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency
por: Cunanan, Kristen M., et al.
Publicado: (2017)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Management of multiple myeloma during COVID-19 pandemic
por: Jethava, YS, et al.
Publicado: (2020)

Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
por: Kyi, Chrisann, et al.
Publicado: (2021)

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study
por: Wagner, Jeffrey, et al.
Publicado: (2018)

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2019)

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2020)

Biological determinants of health disparities in multiple myeloma
por: Smith, Cheryl Jacobs, et al.
Publicado: (2018)

Neuroglial ATP release through innexin channels controls microglial cell movement to a nerve injury
por: Samuels, Stuart E., et al.
Publicado: (2010)

TME17/473: Web-Based Visualization and Processing of Anthropometric Data
por: Lesný, P, et al.
Publicado: (1999)

One statistical test is sufficient for assessing new predictive markers
por: Vickers, Andrew J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_u546g1igi18rumi4korphrtj46